{
    "clinical_study": {
        "@rank": "107444", 
        "arm_group": [
            {
                "arm_group_label": "Interferon alpha 2 b", 
                "arm_group_type": "Active Comparator", 
                "description": "Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks  and then  5 MU (3t/w) for  23 months."
            }, 
            {
                "arm_group_label": "CSF470 vaccine, BCG, Molgramostim", 
                "arm_group_type": "Experimental", 
                "description": "CSF470 vaccine, BCG, Molgramostim\nCSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.\nEach vaccine consist of a mixture of 17,6.106 melanoma cells , from  four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 \u00b5g prot) the first day and rhGM-CSF (Molgramostim 400 \u00b5g, fractionated in four days doses) will be used."
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized, open, Phase II-III study, comparative between treatment with  CSF-470 vaccine ,\n      allogeneic, irradiated with BCG and molgramostin (rHuGM-CSF) as adjuvants and interferon\n      alfa 2b (IFN-alpha2b) treatment , in stages  IIB, IIC o III (AJCC) post-surgery cutaneous\n      melanoma patients.  This study has been approved by ANMAT ( Administraci\u00f3n Nacional de\n      Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT)), number 1556/2011 (www.anmat.gov.ar).\n\n      The study  Institution  is  Instituto M\u00e9dico Especializado Alexander Fleming, Ciudad\n      Aut\u00f3noma de Buenos Aires, Argentina. The Sponsor is Laboratory Pablo Cassar\u00e1 (LPC, S.R.L.).\n\n      Study population include a total of 108 patients (72 patients will receive CSF470 vaccine\n      and 36 patients will receive alpha IFN-alpha 2b) for a total of 24 months.\n\n      CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then\n      one dose every two months for the first year and them every three months for the second\n      year.\n\n      Each vaccine consist of a mixture of 17,6.106 melanoma cells, from  four melanoma cell\n      lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 \u00b5g prot) the\n      first day and rHuGM-CSF (Molgramostim, 400 \u00b5g, fractionated in four days doses) will be\n      used.\n\n      IFN-alpha 2b treatment will consist of s.c. injection of 10 million units (MU) (5 t/w ) for\n      four weeks  and then 5 MU (3t/w) for 23 months.\n\n      Both treatments will also compare quality of life (QOL) and study a possible correlation in\n      the CSF470 vaccine arm between the induced immune response and clinical outcome"
        }, 
        "brief_title": "Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients", 
        "condition": "Cutaneous Melanoma", 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Skin Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically confirmed cutaneous melanoma stages IIB, IIC or III (AJCC)\n\n          -  patients non-detectable disease (NED) after surgery as asserted by CAT scans.\n             Melanoma pts with unknown primary tumor site could be included in the study\n\n          -  life expectancy > 6 months\n\n          -  performance status (ECOG) 0 or 1\n\n          -  Time post surgery not more than 4 months\n\n          -  no chemotherapy, radiotherapy or any biological treatments prior to this study.\n\n          -  patients must have CATscans of brain, thorax, abdomen and pelvis in the 60 previous\n             days to trial enrolling\n\n          -  To have laboratory studies (no more than 15 days  before entering the study)\n\n          -  laboratory eligibility criteria include: hematocrit: \u226535 (hemoglobin > 10,5 gr %);\n             WBC count > 3500/mm3, platelets > 100.000/mm3, total and direct bilirubin, serum\n             oxalacetic transaminase and glutamic pyruvic transaminase < 1.5 fold the upper normal\n             value; LDH \u2264 450 mU/ml\n\n          -  negative serology for HIV, anti-HCV and HBsAg\n\n          -  serum creatinine < 2.0 mg %\n\n          -  all patients must give written informed consent before inclusion in the Study.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding women\n\n          -  Diabetes (Type I or II)\n\n          -  Antecedents of psychiatric diseases\n\n          -  Evidence of active infections\n\n          -  Antecedents of viral or autoimmune hepatitis\n\n          -  Previous autoimmune diseases\n\n          -  Morbid Obesity, defined as CMI (Corporal mass index)>37 kg/m2 in women and >40 kg/m2\n             in men.\n\n          -  Other diseases that require treatment with regular corticoids or non steroids\n             anti-inflammatory drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729663", 
            "org_study_id": "CASVAC0401"
        }, 
        "intervention": [
            {
                "arm_group_label": "CSF470 vaccine, BCG, Molgramostim", 
                "intervention_name": "CSF470 vaccine, BCG, Molgramostim", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Interferon alpha 2 b", 
                "intervention_name": "interferon alpha 2b", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "BCG Vaccine", 
                "Reaferon", 
                "Molgramostim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "melanoma", 
            "irradiated-allogeneic cells", 
            "therapeutic vaccine", 
            "Interferon alpha 2-b"
        ], 
        "lastchanged_date": "November 19, 2012", 
        "location": {
            "contact": {
                "email": "jmordoh@leloir.org.ar", 
                "last_name": "Jos\u00e9 Mordoh, MD, PhD", 
                "phone": "44-11-6323-2900", 
                "phone_ext": "2204"
            }, 
            "facility": {
                "address": {
                    "city": "Buenos Aires", 
                    "country": "Argentina", 
                    "state": "Capital Federal", 
                    "zip": "1426"
                }, 
                "name": "Instituto M\u00e9dico Alexander Fleming"
            }, 
            "investigator": [
                {
                    "last_name": "Jos\u00e9 Mordoh, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mar\u00eda M Barrio, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Argentina"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients", 
        "overall_contact": {
            "email": "jmordoh@alexanderfleming.org", 
            "last_name": "Jos\u00e9 Mordoh, MD, PhD", 
            "phone": "54-11-6323-2900", 
            "phone_ext": "2205"
        }, 
        "overall_contact_backup": {
            "email": "barrio.marcela@gmail.com", 
            "last_name": "Mar\u00eda M Barrio, PhD", 
            "phone": "54-11-6323-2900", 
            "phone_ext": "1110"
        }, 
        "overall_official": {
            "affiliation": "Instituto M\u00e9dico Alexander Fleming", 
            "last_name": "Jos\u00e9 Mordoh, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_outcome": [
            {
                "description": "OS, DFS, Partial or total remission (PR or CR)", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "two years"
            }, 
            {
                "description": "measured according to the NCI-Common Toxicity Criteria", 
                "measure": "security", 
                "safety_issue": "Yes", 
                "time_frame": "two years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729663"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Laboratorio Pablo Cassar\u00e1 S.R.L.", 
            "investigator_full_name": "Jos\u00e9 Mordoh", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "QOL:evaluated with EORTC QLQ-C30 questionnaire; ECOG Performance status", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "two years"
            }, 
            {
                "description": "Induction of immune responses associated to different vaccine doses for  2 years (Trial duration) ]Cellular immunity (DTH) - Humoral immunity", 
                "measure": "Induction of immune responses", 
                "safety_issue": "No", 
                "time_frame": "two years"
            }
        ], 
        "source": "Laboratorio Pablo Cassar\u00e1 S.R.L.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fundacion Sales", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Agencia Nacional de Promocion Cientifica y Tecnica, Argentina", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fundacion Cancer FUCA", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Council of Scientific and Technical Research, Argentina", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Instituto Nacional del C\u00e1ncer, Argentina", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Laboratorio Pablo Cassar\u00e1 S.R.L.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}